|
|
 Previous Article | Table of Contents | Next Article 
p53 gene mutations in multiple myeloma are associated with advanced forms
of malignancy
A Neri, L Baldini, D Trecca, L Cro, E Polli and AT Maiolo
Servizio di Ematologia, Universita di Milano, Ospedale Maggiore,
I.R.C.C.S., Italy.
The frequency and type of p53 gene mutations was investigated in a series
of 52 cases of multiple myeloma (MM) representative of the different
clinical phases and forms of the disease (indolent, 12 cases; chronic, 24
cases; acute/leukemic, 16 cases). DNAs were analyzed for p53 gene mutations
in exons 5 to 9 by polymerase chain reaction (PCR), single-strand
conformation polymorphism (SSCP), and direct sequencing of PCR-amplified
fragments. Point mutations were detected in 7 of 52 patients (13%) (5 at
exon 8; 1 at exon 6; 1 at exon 7), and were specifically associated with
the more advanced and clinically aggressive acute/leukemic forms of MM (7
of 16 [43%].) Three of the mutated cases had been evaluated at clinical
presentation in earlier phases of the disease (indolent or chronic) and
were found to be negative for p53 mutation. Moreover, three patients with
p53 mutation had not received chemotherapy at the time of investigation.
These results support the notion that the development of MM is a multistep
process and suggest that alterations in the p53 gene may represent an
important late event in MM tumor progression.
Volume 81,
Issue 1,
pp. 128-135,
01/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Blood,
November 15, 2008;
112(10):
4235 - 4246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Stuhmer, M. Chatterjee, M. Hildebrandt, P. Herrmann, H. Gollasch, C. Gerecke, S. Theurich, L. Cigliano, R. A. Manz, P. T. Daniel, et al.
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Blood,
November 15, 2005;
106(10):
3609 - 3617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, K. Podar, D. Gupta, B. Lin, G. Young, M. Akiyama, and K. C. Anderson
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells
Blood,
February 15, 2002;
99(4):
1419 - 1427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Renner, J. Weisz, S. Krajewski, M. Krajewska, J. C. Reed, and A. Lichtenstein
Expression of BAX in Plasma Cell Dyscrasias
Clin. Cancer Res.,
June 1, 2000;
6(6):
2371 - 2380.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. H.-L. Ng, A. Kan, Y.-F. Chung, I. H.-N. Wong, K.-W. Lo, N. W. R. Wickham, K. I.-K. Lei, and J. C.-K. Lee
Combined Morphological and Interphase Fluorescence in Situ Hybridization Study in Multiple Myeloma of Chinese Patients
Am. J. Pathol.,
January 1, 1999;
154(1):
15 - 22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Drach, J. Ackermann, E. Fritz, E. Kromer, R. Schuster, H. Gisslinger, M. DeSantis, N. Zojer, M. Fiegl, S. Roka, et al.
Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy
Blood,
August 1, 1998;
92(3):
802 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Rayanade, M. I. Ndubuisi, J. D. Etlinger, and P. B. Sehgal
Regulation of IL-6 Signaling by p53: STAT3- and STAT5-Masking in p53-Val135-Containing Human Hepatoma Hep3B Cell Lines
J. Immunol.,
July 1, 1998;
161(1):
325 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J.-F. Rossi, J. Brochier, and B. Klein
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4727 - 4737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Richelda, D. Ronchetti, L. Baldini, L. Cro, L. Viggiano, R. Marzella, M. Rocchi, T. Otsuki, L. Lombardi, A. T. Maiolo, et al.
A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene
Blood,
November 15, 1997;
90(10):
4062 - 4070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bataille and J.-L. Harousseau
Multiple Myeloma
N. Engl. J. Med.,
June 5, 1997;
336(23):
1657 - 1664.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.W. Lowe, S. Bodis, N. Bardees, A. McClatchey, L. Remington, H.E. Ruley, D.E. Fisher, T. Jacks, J. Pelletier, and D.E. Housman
Apoptosis and the Prognostic Significance of p53 Mutation
Cold Spring Harb Symp Quant Biol,
January 1, 1994;
59(0):
419 - 426.
[Abstract]
[PDF]
|
|
|
|
|
